Food noise as a missing piece in obesity treatment: toward an integrated intervention framework

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Obesity treatment has entered a new era with the widespread adoption of glucagon-like peptide-1 (GLP-1) receptor agonists and a striking patient-reported phenomenon, the silencing of persistent, intrusive food thoughts. Formally defined as “food noise”, persistent thoughts about food perceived as unwanted and/or dysphoric that may cause social, mental, or physical harm, this construct has moved from lay discourse into peer-reviewed science [1], is measurable through validated instruments, including the Ro Allison Indiana Dhurandhar Food Noise (RAID-FN) Inventory and the Food Noise Questionnaire, and resembles cognitive rumination more than physiological appetite [1, 2]. Yet food noise remains absent as an explicit therapeutic target from most obesity treatment frameworks. Recent consensus guidance calls for integrating nutritional and lifestyle strategies alongside GLP-1 therapy [3], and culinary medicine is emerging as a scalable behavioral intervention [4]. However, no prior framework has positioned food noise as the central unifying construct linking pharmacological, culinary-behavioral, and digital monitoring approaches. This Perspective argues that sustainable obesity management requires treating food noise not merely as a symptom to suppress, but as a measurable therapeutic target across neurobiological, culinary-nutritional, and cognitive-behavioral dimensions.

GLP-1 receptors are expressed throughout appetite-regulating and reward-processing circuitry. Merkel et al. identified an endogenous nucleus tractus solitarius (NTS)-to-ventral tegmental area (VTA) circuit in which GLP-1-secreting neurons increase GABAergic inhibition, attenuating dopaminergic reward-seeking activity and providing a plausible neurobiological substrate for food noise reduction during semaglutide and tirzepatide treatment [5]. Cook (2026) further proposed that GLP-1 receptor agonists suppress default mode network hyperactivity, a mechanism through which mindfulness-based practices reduce food preoccupation [6]. This pharmacological window quiets neurobiological food noise and increases patients’ capacity to build behavioral skills. The critical problem is closure upon discontinuation, as food noise reliably returns within days to weeks, and the STEP 1 trial extension demonstrated approximately two-thirds weight regain within one year of semaglutide withdrawal [7]. Three converging problems expose the limits of pharmacotherapy alone: access inequity from cost, insurance gaps, and gastrointestinal side effects disproportionately affecting low-income and minority populations; failure to address environmental and emotional food noise drivers as patients re-enter processed food environments without behavioral skills [2]; and co-occurrence with anxiety, emotional eating, and binge eating requiring targeted psychological intervention.